Clinical trial
Study Evaluating Persistence of Anti-HBs Antibodies in Uraemic Patients…
NCT00445185 · Henogen, Industry · Completed
Key facts
| NCT number | NCT00445185 |
|---|---|
| Title | Study Evaluating Persistence of Anti-HBs Antibodies in Uraemic Patients Receiving Henogen's HBV Vaccine, or Fendrix™ |
| Official title | A Study to Evaluate the Persistence of Anti-HBs Antibodies at Months 12, 24 and 36 in Pre-dialysis or Dialysis Patients Who Have Received a Primary Vaccination Course of Either Henogen's HBV Vaccine, HB-AS02V or GSK Biological's Fendrix™ |
| Lead sponsor | Henogen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis B |
| Intervention type | Biological |
| Interventions | Henogen HB vaccine, Fendrix vaccine |
| Enrollment | 102 |
| Start date | Mar 1, 2007 |
| Primary completion | Jul 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | Mar 8, 2007 |
| Last update posted | Nov 19, 2009 |
| Countries | Belgium, Czechia, Hungary |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: